NRGENE TECHNOLOGIES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 464.8 ILa | -0.94% |
|
-2.19% | +165.45% |
| 20/03 | NRGene Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 30/01 | NRgene Technologies Ltd. Establishes Supree | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 41.54 | 16.07 | 6.068 |
| Enterprise Value (EV) 1 | 22.01 | 5.395 | 1.32 |
| P/E ratio | -4.86 x | -2.59 x | -1.15 x |
| Yield | - | - | - |
| Capitalization / Revenue | 9.31 x | 5.09 x | 3.03 x |
| EV / Revenue | 4.93 x | 1.71 x | 0.66 x |
| EV / EBITDA | -2.63 x | -1.04 x | -0.29 x |
| EV / FCF | -81,25,157 x | -7,94,560 x | -3,71,354 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 2.35 x | 1.32 x | 0.85 x |
| Nbr of stocks (in thousands) | 12,380 | 12,414 | 12,516 |
| Reference price 2 | 3.356 | 1.294 | 0.4848 |
| Announcement Date | 29/03/22 | 30/03/23 | 20/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7.313 | 7.607 | 7.035 | 4.463 | 3.159 | 2.001 |
| EBITDA 1 | -4.127 | -3.257 | -1.696 | -8.367 | -5.194 | -4.501 |
| EBIT 1 | -4.251 | -3.292 | -1.717 | -8.402 | -5.355 | -4.693 |
| Operating Margin | -58.13% | -43.28% | -24.41% | -188.26% | -169.52% | -234.53% |
| Earnings before Tax (EBT) 1 | -4.478 | -3.894 | -3.099 | -8.298 | -6.213 | -5.23 |
| Net income 1 | -4.494 | -3.911 | -3.146 | -8.338 | -6.207 | -5.243 |
| Net margin | -61.45% | -51.41% | -44.72% | -186.83% | -196.49% | -262.02% |
| EPS 2 | -0.5192 | -0.4469 | -0.3600 | -0.6907 | -0.5000 | -0.4200 |
| Free Cash Flow | - | -2.562 | -1.312 | -2.709 | -6.79 | -3.553 |
| FCF margin | - | -33.69% | -18.65% | -60.71% | -214.94% | -177.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 27/12/20 | 27/12/20 | 29/03/21 | 29/03/22 | 30/03/23 | 20/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.21 | 3.6 | - | - | - |
| Net Cash position 1 | 2.79 | - | - | 19.5 | 10.7 | 4.75 |
| Leverage (Debt/EBITDA) | - | -0.3709 x | -2.12 x | - | - | - |
| Free Cash Flow | - | -2.56 | -1.31 | -2.71 | -6.79 | -3.55 |
| ROE (net income / shareholders' equity) | - | 155% | 68% | -137% | -41.5% | -53.8% |
| ROA (Net income/ Total Assets) | - | -46.3% | -26.8% | -34.8% | -15.3% | -20.9% |
| Assets 1 | - | 8.44 | 11.73 | 23.95 | 40.49 | 25.11 |
| Book Value Per Share 2 | -0.1500 | -0.4200 | -0.6300 | 1.430 | 0.9800 | 0.5700 |
| Cash Flow per Share 2 | 0.4400 | 0.3000 | 0.1700 | 0.7100 | 0.9800 | 0.5100 |
| Capex 1 | 0.02 | 0.02 | 0.02 | 0.51 | 0.22 | 0.15 |
| Capex / Sales | 0.23% | 0.3% | 0.3% | 11.32% | 6.87% | 7.5% |
| Announcement Date | 27/12/20 | 27/12/20 | 29/03/21 | 29/03/22 | 30/03/23 | 20/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +165.45% | 16.03M | |
| -19.27% | 26.87B | |
| +21.84% | 11.17B | |
| +0.22% | 4.97B | |
| -21.37% | 771M | |
| +23.03% | 503M | |
| -14.52% | 442M | |
| +0.58% | 308M | |
| -24.02% | 227M | |
| 0.00% | 203M |
- Stock Market
- Equities
- NRGN Stock
- Financials NRGene Technologies Ltd